Xoma’s Acquisition Bid Reaches Critical Juncture

Revised Terms Shape Final Negotiations

The fate of Xoma Royalty’s proposed acquisition of LAVA Therapeutics hangs in the balance as shareholders convene for a decisive vote. The biotechnology firm’s pursuit of its competitor has reached its final stages, with revised terms significantly altering the transaction’s financial dynamics and sending technical signals about Xoma’s stock performance.